<DOC>
	<DOCNO>NCT00862082</DOCNO>
	<brief_summary>The current understanding PR104 justify evaluation PR104 sorafenib patient hepatocellular carcinoma . These include : - Hypoxia . Hepatocellular Carcinoma ( HCC ) likely demonstrate level hypoxia sufficient activate PR104 active metabolite PR104H PR104M . In addition , preclinical model , sorafenib demonstrate increase degree hypoxia tumor follow treatment . - Non-overlapping toxicity . PR104 sorafenib share major toxicity . It anticipate drug administer full single agent dose use combination . - Aldo-keto reductase 1C3 ( AKR1C3 ) . HCC show express high level AKR1C3 lead selective activation PR104 within hypoxic oxic HCC cell . - Preclinical data . The use sorafenib PR104 alone combination hepatocellular carcinoma model demonstrate activity PR104 single agent increase activity PR104 sorafenib use combination . The current study provide estimate activity PR104 subject HCC . This information prove valuable defining future clinical development PR104 , determine PR104 sufficient activity HCC warrant large phase III registration study indication . Primary objective - Phase I : Determine maximum tolerate dose ( MTD ) PR104 use combination standard dose sorafenib - Phase II : Estimate response rate ( RR ) PR104/sorafenib [ Note : Phase II never initiate ] Secondary objectives - Evaluate survival - Evaluate Progression Free Survival ( PFS ) - Evaluate time progression ( TTP ) - Evaluate safety - Evaluate pharmacokinetics ( PK ) sorafenib , PR104 PR104 metabolites - Collect diagnostic biopsy sample determination aldo-keto reductase 1C3 - Collect plasma sample assessment potential biomarkers tumor hypoxia</brief_summary>
	<brief_title>Randomized Phase 1/2 Open-Label Trial PR104 Sorafenib Patients With Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>A randomized phase I/II , multi-center , open-label , study single arm phase I portion determine appropriate dose PR104 combine sorafenib , follow phase II portion randomization sorafenib sorafenib/PR104 . Following informed consent , subject undergo baseline evaluation history , physical exam , blood work disease assessment . Selected subject undergo PK assessment sorafenib , PR104 PR104 metabolite . In phase I portion study , start dose PR104 770 mg/mg2 combination standard dose sorafenib . PR104 administer every 4 week schedule dose PR104 escalate standard phase I fashion ( 3 subject per cohort , dose escalation cohort ) order determine MTD PR104 . Cohorts may expand 12 subject well define toxicity particular dose level . Following determination MTD PR104 , new subject enter phase II portion study . [ Note : Phase II portion never initiate ] In phase II portion study , subject randomize sorafenib , 400 mg , mouth ( PO ) , twice day ( approve dose schedule ) versus sorafenib PR104 dose determine phase I portion study . PR104 administer every 4 week ( one cycle ) . Subjects evaluate week cycle 1 every two week thereafter . A disease assessment perform every two cycle . Subjects progression remove study . Subjects response stable disease may continue study consider beneficial physician .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Advancedstage hepatocellular carcinoma consider nonoperable suitable treatment sorafenib . Subjects demonstrate progression follow initial surgical locoregional therapy eligible Confirmed hepatocellular carcinoma pathological analysis ( tissue aspirate biopsy ) No previous systemic therapy hepatocellular carcinoma Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 ChildPugh liver function class A Life expectancy 12 week Adequate hematologic function [ Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ; platelet count ≥100×10^9 per liter ; hemoglobin ≥8.5 g per deciliter maintain absence red blood cell transfusion ; prothrombin time international normalized ratio ≤1.7 ; prothrombin time ≤2 second control ] Adequate hepatic function ( albumin ≥2.8 g per deciliter ; total bilirubin ≤2 mg per deciliter [ 51.3 μmol per liter ] ; alanine aminotransferase aspartate aminotransferase ≤5 time upper limit normal range ) Adequate renal function ( serum creatinine ≤1.5 time upper limit normal range creatinine clearance ≥60 mL/min ) . At least one untreated target lesion could measure one dimension , accord Response Evaluation Criteria Solid Tumors ( RECIST ) Concomitant systemic antiviral therapy allow Previous molecularly target therapy systemic treatment hepatocellular carcinoma Active concomitant malignancy likely effect primary secondary outcome measure current study Women pregnant , breastfeed plan become pregnant study Men woman reproductivepotential unwilling use effective method contraception study 30 day follow last dose study medication Evidence significant medical disorder laboratory finding , opinion Investigator , compromise subject 's safety study participation : uncontrolled infection infection require concomitant parenteral antibiotic ; uncontrolled diabetes ; congestive heart failure ; myocardial infarction within 6 month study ; chronic renal disease ; coagulopathy ( exclude prophylactic anticoagulation ) Active central nervous system metastatic disease require intervention Less four week since major surgery Known Human Immunodeficiency Virus ( HIV ) positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>